Systematic review: Rectal therapies for the treatment of distal forms of ulcerative colitis

Inflammatory Bowel Diseases

Volumn 21, Issue 7, 2015, Pages 1719-1736

  Cohen, Russell D ^a   Dalal, Sushila R ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

5 ASA; corticosteroid; enema; foam; suppository

Indexed keywords

ALICAFORSEN; CORTICOSTEROID; ENEMA; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT;

COLON MUCOSA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FOAM; GEL; HUMAN; META ANALYSIS; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SUPPOSITORY; TREATMENT RESPONSE; ULCERATIVE COLITIS; COLITIS, ULCERATIVE; RECTAL DRUG ADMINISTRATION;

ADMINISTRATION, RECTAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; HUMANS; REMISSION INDUCTION;

EID: 84932159239     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000379     Document Type: Review

References (72)

1. Kappelman MD, Moore KR, Allen JK, et al. Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci. 2013;58:519-525.
2. Loftus CG, Loftus EV Jr, Harmsen WS, et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis. 2007;13:254-261.
3. Herrinton LJ, Liu L, Lewis JD, et al. Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002. Am J Gastroenterol. 2008;103:1998-2006.
4. Hanauer SB, Present DH, Rubin DT. Emerging issues in ulcerative colitis and ulcerative proctitis: individualizing treatment to maximize outcomes. Gastroenterol Hepatol (N Y). 2009;5:4-16.
5. Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis. a long-Term follow-up of 1116 patients. Dig Dis Sci. 1993;38:1137-1146.
6. Kornbluth A, Sachar DB; The Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501-523.
7. Loew BJ, Siegel CA. Foam preparations for the treatment of ulcerative colitis. Curr Drug Deliv. 2012;9:338-344.
8. Harris MS, Lichtenstein GR. Review article: delivery and efficacy of topical 5-Aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2011;33:996-1009.
9. Seibold F, Fournier N, Beglinger C, et al; Swiss IBD Cohort Study Group. Topical therapy is underused in patients with ulcerative colitis. J Crohns Colitis. 2014;8:56-63.
10. Cohen RD. Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006;24:465-474.
11. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006;23:577-585.
12. Kane SV, Accortt NA, Magowan S, et al. Predictors of persistence with 5-Aminosalicylic acid therapy for ulcerative colitis. Aliment Pharmacol Ther. 2009;29:855-862.
13. Andus T, Kocjan A, Müser M, et al; International Salofalk Suppository OD Study Group. Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. Inflamm Bowel Dis. 2010;16: 1947-1956.
14. Bar-Meir S, Fidder HH, Faszczyk M, et al; The International Budesonide Study Group. Budesonide foam vs. hydrocortisone acetate foam in the treatment of active ulcerative proctosigmoiditis. Dis Colon Rectum. 2003; 46:929-936.
15. Gross V, Bar-Meir S, Lavy A, et al; The International Budesonide Foam Study Group. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Aliment Pharmacol Ther. 2006;23: 303-312.
16. Hanauer S, Good LI, Goodman MW, et al. Long-Term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol. 2000;95:1749-1754.
17. Marteau P, Crand J, Foucault M, et al. Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study. Gut. 1998;42:195-199.
18. Ordas I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012; 380:1606-1619.
19. Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2010;16:338-346.
20. Cohen RD, Woseth DM, Thisted RA, et al. A meta-Analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000;95:1263-1276.
21. Talley NJ, Abreu MT, Achkar JP, et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011;106(suppl 1):S2-S25.
22. Marshall JK, Thabane M, Steinhart AH, et al. Rectal 5-Aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;11:CD004118.
23. Falck-Ytter Y, Kunz R, Guyatt GH, et al. How strong is the evidence?. Am J Gastroenterol. 2008;103:1334-1338.
24. Watanabe M, Nishino H, Sameshima Y, et al. Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation-A placebo-controlled study. Aliment Pharmacol Ther. 2013;38:264-273.
25. Campieri M, Gionchetti P, Belluzzi A, et al. Topical treatment with 5-Aminosalicylic in distal ulcerative colitis by using a new suppository preparation. A double-blind placebo controlled trial. Int J Colorectal Dis. 1990;5:79-81.
26. Campieri M, De Franchis R, Bianchi Porro G, et al. Mesalazine (5-Aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial. Scand J Gastroenterol. 1990;25:663-668.
27. Lamet M, Ptak T, Dallaire C, et al; Mesalamine Study Group. Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study. Inflamm Bowel Dis. 2005;11:625-630.
28. DArienzo A, Panarese A, DArmiento FP, et al. 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial. Am J Gastroenterol. 1990;85:1079-1082.
29. Eliakim R, Tulassay Z, Kupcinskas L, et al. Clinical trial: randomizedcontrolled clinical study comparing the efficacy and safety of a lowvolume vs. a high-volume mesalazine foam in active distal ulcerative colitis. Aliment Pharmacol Ther. 2007;26:1237-1249.
30. Pokrotnieks J, Marlicz K, Paradowski L, et al. Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled study. Aliment Pharmacol Ther. 2000;14:1191-1198.
31. Aumais G, Lefebvre M, Massicotte J, et al. Pharmacokinetics and pilot efficacy of a mesalazine rectal gel in distal ulcerative colitis. Drugs R D. 2005;6:41-46.
32. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987;92:1894-1898.
33. Connolly MP, Poole CD, Currie CJ, et al. Quality of life improvements attributed to combination therapy with oral and topical mesalazine in mild-To-moderately active ulcerative colitis. Digestion. 2009;80:241-246.
34. Cortot A, Maetz D, Degoutte E, et al. Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis. Am J Gastroenterol. 2008;103:3106-3114.
35. Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut. 2005;54:960-965.
36. Vecchi M, Meucci G, Gionchetti P, et al. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Aliment Pharmacol Ther. 2001;15:251-256.
37. Hanauer SB; The U.S. PENTASA Enema Study Group. Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. Inflamm Bowel Dis. 1998;4:79-83.
38. Campieri M, Gionchetti P, Belluzzi A, et al. Optimum dosage of 5-Aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut. 1991;32:929-931.
39. Sutherland LR, Martin F. 5-Aminosalicylic acid enemas in treatment of distal ulcerative colitis and proctitis in Canada. Dig Dis Sci. 1987;32: 64S-66S.
40. Yokoyama H, Takagi S, Kuriyama S, et al. Effect of weekend 5-Aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. Inflamm Bowel Dis. 2007;13:1115-1120.
41. Biddle WL, Greenberger NJ, Swan JT, et al. 5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis. Gastroenterology. 1988;94:1075-1079.
42. Truelove SC, Richards WC. Biopsy studies in ulcerative colitis. Br Med J. 1956;1:1315-1318.
43. Gross V. Topical therapy. Dig Dis. 2012;30(suppl 3):92-99.
44. Marchioni Beery R, Kane S. Current approaches to the management of new-onset ulcerative colitis. Clin Exp Gastroenterol. 2014;7:111-132.
45. De Cassan C, Fiorino G, Danese S. Second-generation corticosteroids for the treatment of Crohn's disease and ulcerative colitis: more effective and less side effects?. Dig Dis. 2012;30:368-375.
46. Hammond A, Andus T, Gierend M, et al; German Budesonide Foam Study Group. Controlled, open, randomized multicenter trial comparing the effects of treatment on quality of life, safety and efficacy of budesonide foam and betamethasone enemas in patients with active distal ulcerative colitis. Hepato-gastroenterology. 2004;51:1345-1349.
47. Hartmann F, Stein J; The BudMesa-Study Group. Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis. Aliment Pharmacol Ther. 2010;32:368-376.
48. Biancone L, Gionchetti P, Del Vecchio Blanco G, et al. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study. Dig Liver Dis. 2007;39:329-337.
49. Gionchetti P, DArienzo A, Rizzello F, et al; The Italian BDP Study Group. Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial. J Clin Gastroenterol. 2005;39:291-297.
50. Lindgren S, Lofberg R, Bergholm L, et al. Effect of budesonide enema on remission and relapse rate in distal ulcerative colitis and proctitis. Scand J Gastroenterol. 2002;37:705-710.
51. Hanauer SB, Robinson M, Pruitt R, et al; U.S. Budesonide Enema Study Group. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. Gastroenterology. 1998;115: 525-532.
52. Danielsson A, Edsbacker S, Lofberg R, et al. Pharmacokinetics of budesonide enema in patients with distal ulcerative colitis or proctitis. Aliment Pharmacol Ther. 1993;7:401-407.
53. Danielsson A, Lofberg R, Persson T, et al. A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis. Scand J Gastroenterol. 1992;27:9-12.
54. Cobden I, al-Mardini H, Zaitoun A, et al. Is topical therapy necessary in acute distal colitis?. Double-blind comparison of high-dose oral mesalazine versus steroid enemas in the treatment of active distal ulcerative colitis. Aliment Pharmacol Ther. 1991;5:513-522.
55. Desrame J, Sabate JM, Agher R, et al. Assessment of hypothalamicpituitary-Adrenal axis function after corticosteroid therapy in inflammatory bowel disease. Am J Gastroenterol. 2002;97:1785-1791.
56. Ginsberg AL, Beck LS, McIntosh TM, et al. Treatment of left-sided ulcerative colitis with 4-Aminosalicylic acid enemas. A double-blind, placebo-controlled trial. Ann Intern Med. 1988;108:195-199.
57. Gandolfo J, Farthing M, Powers G, et al. 4-Aminosalicylic acid retention enemas in treatment of distal colitis. Dig Dis Sci. 1987;32:700-704.
58. Selby WS, Bennett MK, Jewell DP. Topical treatment of distal ulcerative colitis with 4-Amino-salicylic acid enemas. Digestion. 1984;29: 231-234.
59. Miner PB Jr, Wedel MK, Xia S, et al. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. Aliment Pharmacol Ther. 2006;23: 1403-1413.
60. Miner PB Jr, Geary RS, Matson J, et al. Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis. Aliment Pharmacol Ther. 2006; 23:1427-1434.
61. van Deventer SJ, Wedel MK, Baker BF, et al. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol Ther. 2006;23:1415-1425.
62. van Deventer SJ, Tami JA, Wedel MK; European Colitis Study Group. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut. 2004;53:1646-1651.
63. Ingram JR, Thomas GA, Rhodes J, et al. A randomized trial of nicotine enemas for active ulcerative colitis. Clin Gastroenterol Hepatol. 2005;3: 1107-1114.
64. Mahmood A, Melley L, Fitzgerald AJ, et al. Trial of trefoil factor 3 enemas, in combination with oral 5-Aminosalicylic acid, for the treatment of mild-To-moderate left-sided ulcerative colitis. Aliment Pharmacol Ther. 2005;21:1357-1364.
65. Sinha A, Nightingale J, West KP, et al. Epidermal growth factor enemas with oral mesalamine for mild-To-moderate left-sided ulcerative colitis or proctitis. N Engl J Med. 2003;349:350-357.
66. Sandborn WJ, Tremaine WJ, Schroeder KW, et al. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology. 1994;106:1429-1435.
67. Pedersen G, Brynskov J. Topical rosiglitazone treatment improves ulcerative colitis by restoring peroxisome proliferator-Activated receptorgamma activity. Am J Gastroenterol. 2010;105:1595-1603.
68. Miyata M, Kasugai K, Ishikawa T, et al. Rebamipide enemas-new effective treatment for patients with corticosteroid dependent or resistant ulcerative colitis. Dig Dis Sci. 2005;50(suppl 1):S119-S123.
69. van Dieren JM, van Bodegraven AA, Kuipers EJ, et al. Local application of tacrolimus in distal colitis: feasible and safe. Inflamm Bowel Dis. 2009; 15:193-198.
70. Mayberry J. The history of 5-ASA compounds and their use in ulcerative colitis-Trailblazing discoveries in gastroenterology. J Gastrointestin Liver Dis. 2013;22:375-377.
71. Marshall JK, Thabane M, Steinhart AH, et al. Rectal 5-Aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;1:CD004115.
72. Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-Analysis. Gut. 1997;40:775-781.